At the same time, several FOLR1 targeted drugs have good antitumor effects and are currently in phase II/III clinical trials.527–534 Therefore, the use of folate-conjugating strategy in PROTACs technology (folate-caged PROTACs) to achieve the specific delivery of degraders to cancer cells has become a practical method. The gene discussed is FOLR1; the disease is cancer.